Earnings call · Apr–Jun 2026
Fredun Pharmaceuticals Limited
From the company
- Sakhi Panjiyara
- Vinod Shah
- Ketan Patak
Questions came from
- Mayur ParikhVY Capital
- Keshav ToshniwalKarnakala Capital
- Shreya BajajSirin Alpha
- Nabendu Mondal
- Khushi JainShare India Securities
- Ashish MalaniMalani Family Office
- Nirali ShahAshika Investment Managers
- Yash Gupta
- Abhi JainAJ Capital
Topics in this call
Opening remarks
Sakhi Panjiyara
Good morning, everyone, and thank you for joining the Q1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. We have with us today Mr. Fredun Medhora, Managing Director of the company.
Before handing over to Fredun Sir, let me briefly walk you through the company's performance for the first quarter of FY27. During Q1 FY27, stand-alone total income stood at INR228.25 crores, registering a strong Y-on-Y growth of 90.44%. EBITDA stood at INR32.78 crores, reflecting a growth of 92.90% year-on-year growth.
Read the whole call: 73 paragraphs, 9 analysts' questions with every answer.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.